Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors

• Type: Article in International Scientific Journal
• Date: 2019

Authors

Portovedo, S (Author) Other; Gaido, N (Author) Other; Nunes, BD (Author) Other; Nascimento, AG (Author) Other; Rocha, A (Author) Other; Magalhaes, M (Author) Other; Nascimento, GC (Author) Other; de Carvalho, DP (Author) Other; Soares, P (Author) FMUP; Takiya, C (Author) Other; Faria, MD (Author) Other; Miranda Alves, L (Author) Other

Journal

Title: Molecular and Cellular Endocrinology

Vol. 490

Pages: 80-87

ISSN: 0303-7207

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 9 Citations

Scopus - 10 Citations

Other information

Authenticus ID: P-00Q-H3H

DOI: 10.1016/j.mce.2019.04.010

Abstract (EN): Defining biomarkers for invasive pituitary neuroendocrine tumors (PitNETs) is highly desirable. The high mobility group A (HMGA) proteins are among the most widely expressed cancer-associated proteins. Indeed, their overexpression is a frequent feature of human malignancies, including PitNETs. We show that nonfunctioning PitNETs (NF-PitNETs) express significantly higher levels of HMGA1 than somatotropinomas (GHs) and corti-cotropinomas (ACTHs). Furthermore, HMGA2 expression was detected only in NF-PitNETs and was significantly higher in larger tumors than in smaller tumors. HMGA expression analysis generally focuses on nuclear staining. Here, cytoplasmic HMGA staining was also found. PitNETs displayed strong nuclear HMGA1 and strong cytoplasmic HMGA2 immunoreactivity. Interestingly, the HMGA1 and HMGA2 nuclear expression levels were significantly higher in invasive adenomas than in noninvasive adenomas. The highest levels of nuclear HMGA2 were found in GHs. In conclusion, we show that overexpression of nuclear HMGA proteins could be a potential biomarker of invasive PitNETs, particularly HMGA2 for GHs. HMGA2 might be a reliable biomarker for NF-PitNETs.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 8